エピソード

  • HIMS Today - Jul 15: New Partners Fuel Growth

    HIMS Today - Jul 15: New Partners Fuel Growth
    2026/07/15
    Hey there! It's Joey, your friendly neighborhood investor, here to break down today’s stock action. We’re talking about Hims & Hers, and guess what? It was a green day! The stock popped up about 4.25%. Not too shabby, right?

    So, what went down? HIMS had a pretty solid day, bouncing back with some nice gains. You know how it is—some days you're riding high, and other days, it feels like you’re just trying to keep your head above water. Today, though? It was all about those gains.

    Now, why did it happen? Well, there’s a lot of buzz around Hims right now. They’ve got eight new partners on board, which is fueling their push to create this all-in-one health platform. Sounds ambitious, right? But hey, if you’re gonna dream, dream big! Also, their CEO is eyeing a heart attack prediction firm, which he thinks has "unreal" value. That’s got investors feeling optimistic. On top of that, they’re gearing up for a call on August 10 to discuss their latest health platform results. So, there’s definitely a lot of action happening behind the scenes.

    But it’s not all sunshine and rainbows. There’s some FDA scrutiny on their peptide products, and Citi just dropped a note saying there’s a “big caveat” to Amazon’s GLP-1 push that could impact HIMS. So, while things are looking good now, there are some potential bumps in the road to keep an eye on.

    So, what’s the takeaway? Hims & Hers is in the spotlight with some new partnerships and ambitious plans, but they’ve got some challenges ahead too. Just a friendly reminder that the market can be wild, so always keep that in mind!

    Alright, that’s a wrap for today! Just here to keep you in the loop, so remember, this isn’t financial advice—just some friendly info. Catch you later!
    続きを読む 一部表示
    2 分
  • HIMS Today - Jul 14: Amazon's GLP-1 War Hits HIMS

    HIMS Today - Jul 14: Amazon's GLP-1 War Hits HIMS
    2026/07/14
    Hey, what’s up? It’s Joey here, your friendly neighborhood investor breaking down today’s market moves. Let’s talk about Hims & Hers, or HIMS for short. Today was a bit of a rough ride; the stock was down about 1.19%.

    So, what happened? Well, it looks like HIMS got a little smoked after some news about Amazon ramping up its GLP-1 competition with Ozempic. Yeah, that one stung. Investors were clearly worried about how that might affect HIMS' growth, especially since they’re all about health and wellness products. When big players like Amazon step into the ring, it can get a bit dicey for smaller companies.

    Now, why did people hit the sell button so fast? There’s been chatter around the whole AI healthcare scene, and with earnings calls coming up, folks are on high alert. HIMS is set to drop their Q2 results on August 10, and everyone’s trying to figure out if they’ll impress or flop. Plus, there was some buzz about insider share sales, which usually raises eyebrows. It’s like a little red flag that makes people think twice before holding onto their shares.

    On a brighter note, HIMS did schedule that call to discuss their latest health platform results, which could be a big deal. If they have good stuff to share, it might just turn the tide for them. Just keep an eye on that.

    So yeah, that’s the scoop on HIMS today. It was a tough day, but these things happen in the market. Remember, I’m just here to share what’s happening, not to give any financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • HIMS Today - Jul 13: New Partners, FDA Meeting Buzz

    HIMS Today - Jul 13: New Partners, FDA Meeting Buzz
    2026/07/13
    Hey, what’s up? It’s Joey here, your go-to guy for stock chatter. I’ve been investing for a while, and today we’re talking about Hims & Hers, or HIMS for short. It was a bit of a mixed bag today, barely up by about a third of a percent. Not a big move, but hey, at least it wasn’t a total flop.

    So, what went down? HIMS is trying to shake things up with eight new partnerships, aiming to build this all-in-one health platform. Sounds cool, right? But here’s the kicker: they just had their worst week in two months. Ouch. They’re also gearing up for a big FDA meeting about their peptides campaign, which could be a game-changer for them.

    Now, why the mixed vibes? Well, on one hand, those new partnerships are exciting and could signal growth, but on the flip side, there’s chatter about whether their GLP-1 strategy has backfired. That’s a fancy way of saying they might have bet on the wrong horse. Investors are probably feeling a bit jittery with all this back-and-forth.

    And just to keep it real, the volume today was way off compared to their average. Like, they only had about 1.6 million shares traded when they usually see over 16 million. That tells me people might be sitting on the sidelines, waiting to see how this FDA meeting goes.

    One thing worth keeping an eye on is that potential rally buzz. Some fund managers are saying HIMS could rally up to 60% this week if the stars align. I mean, that sounds great, but let’s keep those expectations in check, yeah?

    So, to wrap it up, HIMS is in a bit of a tug-of-war between new opportunities and some challenges. It’s definitely a wait-and-see moment. Just remember, this is all for info and fun, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • HIMS Today - Jul 12: Stock Takes a Hit

    HIMS Today - Jul 12: Stock Takes a Hit
    2026/07/12
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down with Hims & Hers today. So, HIMS had a rough day, dropping about 3%. Yeah, that one stung.

    The stock opened lower and just kept slipping. By the end of the day, it was down to $34.38. The trading volume was pretty active, too, with nearly 12 million shares changing hands. Not super surprising since folks were clearly feeling the pressure.

    So, why the dip? Well, a few reasons popped up. First off, there’s this PPI report that’s making waves in the market. It’s got investors on edge about inflation and, honestly, that’s never a good vibe for stocks like HIMS. Plus, there’s chatter around their GLP-1 drug strategy. Some analysts are saying it might’ve backfired, which isn’t great news for the company’s future plans. And then there was that brutal Q1 report that left a bad taste in everyone's mouth. Just a perfect storm of negativity, really.

    Oh, and here’s a little nugget: some investors still think HIMS could turn things around with their partnerships with companies like Novo and Lilly. They’re even dubbing it the “Netflix of healthcare.” Sounds ambitious, right? But, hey, we’ll see how that plays out.

    So, yeah, a tough day for HIMS. But remember, this is just a snapshot of the moment. Stocks go up and down, and this is all just part of the wild ride of investing. Keep your head up, and thanks for hanging out with me today! Just a reminder, I’m here to share info and have fun, not to give you any financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • HIMS Today - Jul 11: Amazon's GLP-1 Moves Impact Stock

    HIMS Today - Jul 11: Amazon's GLP-1 Moves Impact Stock
    2026/07/11
    Hey there! It’s Joey here, your friendly neighborhood investor. Been in the game for a while and today we’re talking about Hims & Hers, ticker HIMS. Spoiler alert: it was a red day, down about 3%. Ouch!

    So, what went down? HIMS got smoked today, dropping a solid chunk of change. The stock dipped after Amazon decided to ramp up its game in the GLP-1 space, which is a big deal. These GLP-1 drugs, like Ozempic, have been the hot topic lately, and now with Amazon stepping in, it’s shaking things up a bit for HIMS.

    Now, why did this matter? Well, investors got a little spooked. Amazon’s entry into this market means more competition, and that can make people nervous about HIMS’ growth prospects. It’s like when your favorite pizza place suddenly has a new rival across the street – you start wondering if they’ll still get your business. Plus, Truist put a hold on HIMS, giving it a $23 target price, which isn’t exactly a vote of confidence. Combine that with some chatter about valuation concerns, and you’ve got a recipe for a sell-off.

    And here’s a fun fact to keep in mind: there’s been a lot of buzz around AI healthcare bets as earnings season approaches. That could shake things up for HIMS, too, especially with all the focus on tech in healthcare lately.

    So yeah, today was a bit rough for Hims & Hers. But hey, that’s how the market rolls sometimes. Just remember, this is all for info and entertainment. No financial advice here, just a friendly chat about stocks. Catch you later!
    続きを読む 一部表示
    1 分
  • HIMS Today - Jul 10: Stock Takes a Hit

    HIMS Today - Jul 10: Stock Takes a Hit
    2026/07/10
    Hey there! It’s Joey here, your friendly neighborhood investor, breaking down what went down today in the stock world. Today’s focus is Hims & Hers, and it was a red day for them, down about 4.17%. Yeah, that one stung a bit.

    So, here’s the scoop. HIMS started off a bit shaky and just couldn’t catch a break. The volume was pretty low compared to usual, which usually isn’t a great sign. I mean, when people aren’t trading as much, it often means they’re not feeling too confident.

    Now, why the drop? A couple of things played into it. First off, Truist came out and said they’re sticking with a “Hold” rating on HIMS, throwing a $23 price target out there. With all the buzz around GLP-1 drugs, there’s some concern about how that’ll affect HIMS’s business model. Plus, there were some mixed signals from Citi, suggesting that while there’s a “big caveat” in Amazon’s GLP-1 push, it might limit risks for HIMS. But still, uncertainty is never good for stock prices, you know?

    Also, there was talk about HIMS bulking up their debt raise to $350 million for a buyout, and that usually makes investors a bit jittery. It’s like, “Why are you raising that much debt?” People want to see companies grow without piling on the loans. And with all this chatter about valuation and whether it's already too rich, it just added to the overall anxiety.

    Now, on the horizon, keep an eye out for any updates regarding their AI push and how that’s going to roll out. That could be a game-changer if they play their cards right.

    So, yeah, it was a tough day for HIMS. But that’s the market for you—up and down like a roller coaster. Just remember, this recap is for your info and entertainment, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • HIMS Today - Jul 09: Mixed Signals and New Partners

    HIMS Today - Jul 09: Mixed Signals and New Partners
    2026/07/09
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down today with Hims & Hers, ticker HIMS. Spoiler alert: it was a red day, but just barely. The stock dipped 0.08%. Yeah, that one stung a bit.

    So, what happened? Well, HIMS opened lower and kinda just hung around that level all day. Trading volume was way off too, like, way below average. Usually, we see a lot more action, but today it felt like people were just sitting on their hands.

    Now, why did this happen? A few things are swirling around. BofA bumped up their price target for HIMS to $37, which sounds good, right? But despite that, investors seemed a bit hesitant. You know how it goes—sometimes even positive news doesn't light a fire under the stock. Plus, there’s chatter about Hims & Hers bringing on eight new partners to boost their health platform. That’s cool, but it seems like the market is still trying to wrap its head around all of it. Some folks think the market just doesn’t get the potential here yet.

    Also, there was some buzz about the CEO eyeing a heart attack prediction firm, which could be a game-changer. But again, the stock just didn’t react the way you might expect. It’s like people are waiting for something more concrete before jumping back in.

    Looking ahead, it’s worth noting that the overall sentiment seems mixed. Even with new partnerships and a higher target from BofA, there’s still a lot of skepticism floating around. So, folks are definitely watching closely to see if this turns into something more substantial.

    To wrap it up, Hims & Hers had a pretty uneventful day, but there’s some interesting stuff brewing under the surface. Keep your eyes peeled, and remember, this is just for fun and info, not financial advice. Catch ya later!
    続きを読む 一部表示
    2 分
  • HIMS Today - Jul 09: Stock Stagnates Despite Buzz

    HIMS Today - Jul 09: Stock Stagnates Despite Buzz
    2026/07/09
    Hey there! I’m Joey, your friendly neighborhood investor, here to break down what went down with Hims & Hers today. So, let’s talk about HIMS. Today was a pretty flat day for the stock—no movement, just hanging around at $36.07.

    Now, what’s the scoop? Well, it was a quiet day in terms of action. The stock didn’t really budge at all. I mean, zero percent change. It’s like it just decided to take a chill pill. Volume was way below average too, like people just weren’t that interested.

    So why the snooze-fest? A couple of things are worth mentioning. First off, BofA just raised their price target for HIMS to $37, which is a good sign, but apparently, that didn’t get anyone hyped. There are also mentions of new partnerships that could help Hims & Hers build this all-in-one health platform, which sounds cool, but again, no one seemed to care today. It’s like the market was just in a mood to ignore all the good news.

    And get this, there’s chatter about the CEO eyeing a heart attack prediction firm, which is kind of a big deal. People are saying that could add some serious value, but it looks like the stock didn’t catch the memo. Maybe folks are just waiting for real action instead of just talk.

    One thing to keep an eye on is that Hims & Hers is trying to expand its services, and they’ve got some new partners lined up. So, while today was a snoozer, there’s potential for some exciting stuff to come down the line.

    Alright, that’s a wrap for today! Just remember, I’m here to keep you in the loop, but this isn’t financial advice. Always do your own thing when it comes to investing. Catch you later!
    続きを読む 一部表示
    1 分